Core Viewpoint - AstraZeneca (AZN.US) reported a strong performance in Q3, with total revenue increasing by 12% year-over-year to $15.191 billion, driven by robust sales of key cancer and diabetes drugs [1] Financial Performance - Total revenue for Q3 reached $15.191 billion, marking a 12% year-over-year growth [1] - Core earnings per share (EPS) were $2.38, exceeding market expectations of $2.27 [1] Future Guidance - The company reaffirmed its full-year revenue growth target of high single digits and core EPS growth of low double digits, aligning with market expectations [1] - AstraZeneca plans to announce a full-year dividend of $3.20 per share for 2025, up from $3.10 last year [1]

Core Insights - AstraZeneca (AZN.US) shares rose over 4% pre-market, reaching $84.92 following the release of its Q3 earnings report [1] - The company reported a 12% year-over-year increase in total revenue to $15.191 billion, with core earnings per share (EPS) of $2.38, exceeding market expectations of $2.27, driven by strong sales of key cancer and diabetes drugs [1] - For the first nine months, revenue grew by 10% year-over-year to $43.236 billion, with core EPS at $7.04 [1] - AstraZeneca reaffirmed its guidance for the full year, expecting high single-digit revenue growth and low double-digit core EPS growth, aligning with market expectations [1] - The company plans to announce a full-year dividend of $3.20 per share for 2025, up from $3.10 last year [1]

Core Viewpoint - AstraZeneca reported strong third-quarter results, with total revenue increasing by 12% year-over-year to $15.191 billion, driven by robust sales of key cancer and diabetes drugs [1] Financial Performance - Total revenue for the first nine months grew by 10% year-over-year to $43.236 billion, with core earnings per share at $7.04 [1] - Core earnings per share for the third quarter were $2.38, exceeding market expectations of $2.27 [1] Future Guidance - The company reaffirmed its guidance for high single-digit revenue growth and low double-digit growth in core earnings per share for the full year, aligning with market expectations [1] - AstraZeneca plans to announce a full-year dividend of $3.20 per share for 2025, up from $3.10 last year [1]

格隆汇11月6日｜阿斯利康公布第三季度业绩，总收入同比增长12%至151.91亿美元，核心每股盈利为 2.38美元，高于市场预期的2.27美元，受惠于重磅癌症及糖尿病药物销售理想。首九个月收入同比增长 10%至432.36亿美元，核心每股盈利为7.04美元。公司重申全年收入将实现高单位数增长，以及核心每 股盈利低双位数增长，与市场预期基本一致。公司计划宣布2025年全年股息为每股3.2美元，而去年为 3.1美元。 ...